🔎 Trials Near Me

Akèy › Astrositòm › Illinois

Etid klinik pou Astrositòm nan Illinois

9 etid pou Astrositòm ap chèche patisipan nan sit nan Illinois.

Vil nan Illinois

Tèks ofisyèl etid la (Anglè)

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  • OSF Saint Joseph Medical Center, Bloomington
  • Illinois CancerCare-Bloomington, Bloomington
  • Illinois CancerCare-Canton, Canton
  • ak 18 plis
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07215910

Targeted Pediatric High-Grade Glioma Therapy

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteEtid obsèvasyon
12 Months – 39 Years · Tout sèks · Mizajou Sep 8, 2026 · NCT05839379

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06860594

Study of Olutasidenib and Temozolomide in HGG

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteFaz 2
Laj 12 a 39 · Tout sèks · Mizajou Sep 1, 2026 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • University of Chicago, Chicago
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05303519

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

  • Research Site, Chicago
Ap rekriteFaz 1/2
Laj 18 a 130 · Tout sèks · Mizajou Aug 12, 2026 · NCT05417594

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteFaz 1 bonèVolontè an sante akeyi
Laj 1 a 21 · Tout sèks · Mizajou Jun 29, 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteFaz 2
12 Months – 39 Years · Tout sèks · Mizajou May 29, 2026 · NCT05843253

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.